Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Single-Agent Ibrutinib As First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL) in Routine Clinical Practice in Spain

Pau Abrisqueta Costa, Javier Loscertales, MD, Maria Jose Terol, Angel Ramirez Payer, Macarena Ortiz Pareja, Inmaculada Perez, Carolina Cuellar, Margarita Fernandez De La Mata, Alicia Rodriguez, MD, Ana Lario, Julio Delgado, MD, Ana Cristina Godoy, PhD, Jose M Arguiñano, Maria José Berruezo, Ana C Oliveira, MD PhD, Jose Angel Hernandez-Rivas, MD PhD, María-Dolores García-Malo, MD, Angeles Medina, MD, Paloma García Martín, Santiago Osorio-Prendes, MD, Patricia Baltasar, Miguel Fernandez, MD, Fernando Marco, María-Jesús Vidal, Alicia Susana Smucler Simonovich, Montserrat Lopez Rubio, PhD, Isidro Jarque, Alexia Suárez Cabrera, Ruben Fernandez, MD, Aima Lancharro Anchel, Eduardo Rios Herranz, Carmen Losada, Ernesto Pérez Persona, Ricardo Francisco Garcia, Dr., Rafael Ramos, Lucrecia Yáñez, MD PhD, Jose Luis Bello, MD, Cristina Loriente, Miguel Villanueva

Blood (2020) 136 (Supplement 1): 32–33.

https://doi.org/10.1182/blood-2020-136036

Published: 2020

Journal Articles

Derived from a Platform of Innovative Therapeutic Molecular Clusters (TMC), Ag5 Is a Highly Potent and Differentiated Molecule That Promises to be Efficacious in Hard-to-Treat Hematological Cancers

Vanesa Porto González, Carmen Carneiro, Vanesa Santos, Erea Borrajo, Blanca Dominguez, Anxo Vidal, Jose Luis Bello, David Buceta, Arturo Lopez-Quintela, Martin Treder, Fernando Dominguez

Blood (2020) 136 (Supplement 1): 23.

https://doi.org/10.1182/blood-2020-136618

Published: 2020

Journal Articles

Idelalisib for Relapsed/Refractory Follicular Lymphoma: Retrospective Study from Spanish Lymphoma Group Geltamo (GELT-IDE-2018-02)

Blood (2019) 134 (Supplement_1): 5249.

https://doi.org/10.1182/blood-2019-125921

Published: 2019

Journal Articles

Extranodal Natural Killer/T-Cell Lymphoma Nasal Type in 87 Cases from Spain: Clinical Presentation, Treatment and Prognostic Factors. Study from the Geltamo Group

Blood (2018) 132 (Supplement 1): 1637.

https://doi.org/10.1182/blood-2018-99-110792

Published: 2018

Journal Articles

Long-term results of a phase 2 study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma

Blood (2017) 130 (15): 1772–1774.

https://doi.org/10.1182/blood-2017-07-795302

Published: 2017

Journal Articles

A Phase 2 Study from Spanish Geltamo Group Investigating the Efficacy and Safety of Bendamustine As Part of Conditioning Regimen for Autologous Stem-Cell Transplantation in Patients with Aggressive Lymphomas: Second Interim Analysis

Blood (2014) 124 (21): 2524.

https://doi.org/10.1182/blood.V124.21.2524.2524

Published: 2014

Journal Articles

GEM2005 trial update comparing VMP/VTP as induction in elderly multiple myeloma patients: do we still need alkylators?

Blood (2014) 124 (12): 1887–1893.

https://doi.org/10.1182/blood-2014-05-573733

Published: 2014

Journal Articles

Phase III Trial Of Bortezomib, Melphalan, and Prednisone (VMP) Versus Bortezomib, Thalidomide, and Prednisone (VTP) In Elderly Multiple Myeloma (MM) Patients: Update Follow-Up, Patterns Management Of First Relapse/Progression

Blood (2013) 122 (21): 1973.

https://doi.org/10.1182/blood.V122.21.1973.1973

Published: 2013

Journal Articles

HLA specificities are related to development and prognosis of diffuse large B-cell lymphoma

Blood (2013) 122 (8): 1448–1454.

https://doi.org/10.1182/blood-2013-02-483420

Published: 2013

Includes: Supplemental data

Journal Articles

Final Results of a Multicenter Phase II Trial with Bendamustine and Rituximab As First Line Treatment for Patients with MALT Lymphoma (MALT-2008–01)

Antonio Salar, MD, Eva Domingo-Domenech, MD, Carlos Panizo, Concepción Nicolás, MD, Joan Bargay, Ana Muntanola, MD, Miguel Canales, Jose Luis Bello, MD, juan Manuel Sancho, Sr., MD, Jose Francisco Tomas, MD, María José Rodriguez, MD, Francisco-Javier Penalver, Luis Palomera, MD, Carlos Grande, José J Sánchez-Blanco, MD, Reyes Arranz, MD, Eulogio Conde, Dolores Caballero, MD, Carlos Montalban

Blood (2012) 120 (21): 3691.

https://doi.org/10.1182/blood.V120.21.3691.3691

Published: 2012

Journal Articles

Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial

Blood (2012) 120 (13): 2581–2588.

https://doi.org/10.1182/blood-2012-05-427815

Published: 2012

Includes: Supplemental data

Journal Articles

Influence of Genetic Polymorphisms in CYP1A2 , CYP2C19, CYP3A4 , GSTP1 , MDR1 and PSMB5 Genes in Toxicity and Response to Induction Therapy in Multiple Myeloma Patients Included in the Trial of the Spanish PETHEMA/GEM 05 for Newly Diagnosed MM Elderly Patients (Age 65 or More)

Blood (2011) 118 (21): 1412.

https://doi.org/10.1182/blood.V118.21.1412.1412

Published: 2011

Journal Articles

Stratification Approach for Splenic Marginal Zone Lymphoma Based on Hemoglobin, Platelet Count, High LDH and Extrahilar Lymphadenopathy: The HPLL/ABC System

Carlos Montalban, MD, PhD, Victor Abraira, PhD, Luca Arcaini, Eva Domingo-Domenech, MD, Pablo Guisado-Vasco, MD, PhD, Emilio Iannitto, MD, Manuela Mollejo, MD, Estella Matutes, Andrés JM Ferreri, MD, Antonio Salar, MD, PhD, Andrea Carpaneto, MD, Ricardo Pérez, MD, Jose Luis Bello, Miguel Hernandez, Dolores Caballero, MD, Miguel A. Piris, MD, PhD

Blood (2011) 118 (21): 1583.

https://doi.org/10.1182/blood.V118.21.1583.1583

Published: 2011

Journal Articles

Targeting the Apoptotic Pathway by TW-37, a Novel Bcl-2 Family Small Molecule Inhibitor, In CLL Primary Samples

Beatriz Herreros, Shaomeng Wang, Maria E. Rodriguez, Margarita Sanchez-Beato, Elena Domenech, Raul Cordoba, Julio Delgado, Jose A Garcia-Marco, MD, PhD, Juan F. Garcia, José Francisco Tomás, Joaquín Martínez-López, Jose Luis Bello, Antonia Rodriguez, Raquel Villuendas, Miguel A. Piris

Blood (2010) 116 (21): 2470.

https://doi.org/10.1182/blood.V116.21.2470.2470

Published: 2010

Journal Articles

Clinical Outcome According to Both Cytogenetic Abnormalities (CA) Detected by Fluorescence In Situ Hibridization (FISH) and Hyperdiploidy Assessed by Flow Cytometry (FCM) In Elderly Newly Diagnosed Myeloma Patients Treated with A Bortezomib-Based Combination

Blood (2010) 116 (21): 309.

https://doi.org/10.1182/blood.V116.21.309.309

Published: 2010

Journal Articles

A Prospective, Multicenter, Randomized, Trial of Bortezomib/Melphalan/Prednisone (VMP) Versus Bortezomib/Thalidomide/Prednisone (VTP) as Induction Therapy Followed by Maintenance Treatment with Bortezomib/Thalidomide (VT) Versus Bortezomib/Prednisone (VP) in Elderly Untreated Patients with Multiple Myeloma Older Than 65 Years.

Blood (2009) 114 (22): 3.

https://doi.org/10.1182/blood.V114.22.3.3

Published: 2009

Journal Articles

Identification of Molecular Risk Score in Advanced Hodgkin Lymphoma: Integrating Tumor and Microenvironment Signatures.

Beatriz Sánchez-Espiridión, Carlos Montalbán, Mónica García-Cosio, Jose García-Laraña, Javier Menarguez, Pilar Sabin, Rafael Ramos, José Rodríguez, Francisco Mestre, Miguel Canales, Francisco Javier Alves, Araceli Canovas, Carmen Camarero, Antonio Salar, Sergi Serrano, Angel Castaño, Pedro Sánchez-Godoy, Águeda Bas, Reyes Arranz, Agustín Acevedo, Concepción Rayón, Manuel F. Fresno, Carlos Santonja, Jose Luis López, Manuela Mollejo, Miguel A. Cruz, Hugo Álvarez-Arguelles, Marta LLanos, Carmen Martín, Rafael Martínez, Joaquín González-Carrero, Concepción Poderos, Francisco Mazorra, Eulogio Conde, Teresa Flores, Ramón García-Sanz, Jerónimo Forteza, Máximo Fraga, Jose Luis Bello, María Jose Mestre, Miguel Méndez, Rubén Quibén, Luz Borbolla, Ana Marin-Niebla, Eduardo Ríos, Manuel M. Morente, Miguel A. Piris, Juan F. García

Blood (2009) 114 (22): 3660.

https://doi.org/10.1182/blood.V114.22.3660.3660

Published: 2009

Journal Articles

High-Resolution SNP 6.0 Array Profiling Discloses Novel Genomic Aberrations in Polycythemia Vera and Essential Thrombocythemia.

Marta Anna Sobas, Teresa Gonzalez, Manuel Perez-Encinas, Celsa Quinteiro, Jose Diaz, Natalia Alonso, Angeles Bendaña, Marta Sonia Gonzalez, Maria-Jose Rabuñal, Jose Luis Bello-Lopez

Blood (2009) 114 (22): 1898.

https://doi.org/10.1182/blood.V114.22.1898.1898

Published: 2009

Journal Articles

Study of the Relation Between the Time Course of the JAK2V617F Allele Burden and the Clinical Evolution in Patients with Myeloproliferative Neoplasms (MPN); A Single Center Study

Marta Anna Sobas, Manuel Pérez-Encinas, Celsa Quinteiro, Teresa González, Sandra Suaréz, Natalia Alonso, José Díaz, Angeles Bendaña, Marta Sonia González, Jose-Luis Bello

Blood (2008) 112 (11): 5250.

https://doi.org/10.1182/blood.V112.11.5250.5250

Published: 2008

Journal Articles

Bortezomib (Velcade)-Melphalan-Prednisone (VMP) Versus Velcade- Thalidomide-Prednisone (VTP) in Elderly Untreated Multiple Myeloma Patients: Which Is the Best Partner for Velcade: An Alkylating or An Immunomodulator Agent?

Maria-Victoria Mateos, Albert Oriol, Joaquín Martínez, Ma Teresa Cibeira, Raquel de Paz, Ma José Terol, José García-Laraña, Enrique Bengoechea, Rafael Martínez, Alejandro Martin, Felipe de Arriba, Luis Palomera, José Hernández, Jose-Luis Bello, María-Luisa Martín, Yolanda González, Joan Blade, MD, Juan José Lahuerta, J.F San Miguel, MD, PhD

Blood (2008) 112 (11): 651.

https://doi.org/10.1182/blood.V112.11.651.651

Published: 2008

NARROW

Single-Agent Ibrutinib As First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL) in Routine Clinical Practice in Spain

Derived from a Platform of Innovative Therapeutic Molecular Clusters (TMC), Ag5 Is a Highly Potent and Differentiated Molecule That Promises to be Efficacious in Hard-to-Treat Hematological Cancers

Idelalisib for Relapsed/Refractory Follicular Lymphoma: Retrospective Study from Spanish Lymphoma Group Geltamo (GELT-IDE-2018-02)

Extranodal Natural Killer/T-Cell Lymphoma Nasal Type in 87 Cases from Spain: Clinical Presentation, Treatment and Prognostic Factors. Study from the Geltamo Group

Long-term results of a phase 2 study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma

A Phase 2 Study from Spanish Geltamo Group Investigating the Efficacy and Safety of Bendamustine As Part of Conditioning Regimen for Autologous Stem-Cell Transplantation in Patients with Aggressive Lymphomas: Second Interim Analysis

GEM2005 trial update comparing VMP/VTP as induction in elderly multiple myeloma patients: do we still need alkylators?

Phase III Trial Of Bortezomib, Melphalan, and Prednisone (VMP) Versus Bortezomib, Thalidomide, and Prednisone (VTP) In Elderly Multiple Myeloma (MM) Patients: Update Follow-Up, Patterns Management Of First Relapse/Progression

HLA specificities are related to development and prognosis of diffuse large B-cell lymphoma

Final Results of a Multicenter Phase II Trial with Bendamustine and Rituximab As First Line Treatment for Patients with MALT Lymphoma (MALT-2008–01)

Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial

Influence of Genetic Polymorphisms in CYP1A2 , CYP2C19, CYP3A4 , GSTP1 , MDR1 and PSMB5 Genes in Toxicity and Response to Induction Therapy in Multiple Myeloma Patients Included in the Trial of the Spanish PETHEMA/GEM 05 for Newly Diagnosed MM Elderly Patients (Age 65 or More)

Stratification Approach for Splenic Marginal Zone Lymphoma Based on Hemoglobin, Platelet Count, High LDH and Extrahilar Lymphadenopathy: The HPLL/ABC System

Targeting the Apoptotic Pathway by TW-37, a Novel Bcl-2 Family Small Molecule Inhibitor, In CLL Primary Samples

Clinical Outcome According to Both Cytogenetic Abnormalities (CA) Detected by Fluorescence In Situ Hibridization (FISH) and Hyperdiploidy Assessed by Flow Cytometry (FCM) In Elderly Newly Diagnosed Myeloma Patients Treated with A Bortezomib-Based Combination

Identification of Molecular Risk Score in Advanced Hodgkin Lymphoma: Integrating Tumor and Microenvironment Signatures.

High-Resolution SNP 6.0 Array Profiling Discloses Novel Genomic Aberrations in Polycythemia Vera and Essential Thrombocythemia.

Study of the Relation Between the Time Course of the JAK2V617F Allele Burden and the Clinical Evolution in Patients with Myeloproliferative Neoplasms (MPN); A Single Center Study

Bortezomib (Velcade)-Melphalan-Prednisone (VMP) Versus Velcade- Thalidomide-Prednisone (VTP) in Elderly Untreated Multiple Myeloma Patients: Which Is the Best Partner for Velcade: An Alkylating or An Immunomodulator Agent?

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only